The collaboration will make use of Freeslate products and services, including technology development, microscale workflows, and Freeslate’s Lab Execution and Analysis (LEA) software, which will enable gains in R&D productivity and innovation.
Freeslate’s integrated workflows are managed by its LEA software platform which creates a single, experimental environment that helps in scientific decision making.
Freeslate CEO John Senaldi said the formulation of protein therapeutics is a cause of concern for pharmaceutical companies.
"High throughput research can enable significant steps forward in both understanding and addressing the challenges of aggregation and particulation in protein drug products," Senaldi added.